Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination
Gevorg Tamamyan shared on LinkedIn:
“As I mentioned in my earlier post, we are ready in Armenia! I urge my dear friends at Agenus to consider Armenia as the first country to register BOT/BAL combination! We started the clinical trial for another indication – Non-Small Cell Lung Cancer (NCT06322108) just a month ago and in one month already 3 patients enrolled and 1 is in the process of enrollment! The team is ready and we will be happy to host and provide care for any patient from around the world! ”
Source: Gevorg Tamamyan/LinkedIn
Gevorg Tamamyan is the Editor-in-chief of OncoDaily, President-Elect of SIOP Asia Continental Branch and Pediatric Oncology East and Mediterranean (POEM) Group, and the CEO of the Immune Oncology Research Institute (IMMONC).
He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023